INTRODUCTION

Obesity is a medical condition in which excess body fat gets accumulated to the extent that it may produce an adverse effect on health, leading to reduced life span and/or increased health problems. It is one of the leading causes of death worldwide, with increasing prevalence especially among adults and children, and is considered as one of the most serious public health problems of the 21st century. Obesity occurs mainly due to chronic imbalance between energy intake and energy expenditure. High intake of dietary fat, poor exercise, sedentary lifestyle, genetic susceptibility and metabolic errors in energy utilization are some of the major causes of obesity. Obesity increases the likelihood of various diseases, particularly heart disease, type 2 diabetes, breathing difficulties during sleep (Sleep Apnea), gallbladder disease, gallstones, Gout, osteoarthritis and certain types of cancer.

Obesity is a challenging clinical condition to treat, because of their complex environmental components. Efforts to develop innovative anti-obesity drugs with benefits for metabolic syndrome have been recently intensified. Moreover, due to absolute etiology of obesity, non-availability of drugs for its treatment, short-term efficacy and limiting contraindication and side effects of available drugs, the treatment is not satisfactory and thus there is a demand for search of new safer ones for combating this epidemic.

Traditional medicine/herbal medicine has been with us for ages but there has been a renewed interest in the subject in the recent past due to its low cost, efficacy and safety. Also, the World Health Organization (WHO) has recommended that this area warrants attention. Carica papaya L. (papaya) is one of the most commonly consumed fruit by the people throughout the world. It has various health benefits due to its rich antioxidant substances. However, little is known about its effect on obesity. Therefore this study was designed with the aim to evaluate the anti-obesity potential of aqueous fruit extract of Carica papaya L. on high fat cafeteria diet induced obese rats.

MATERIALS AND METHODS

Plant Material and Extraction Procedures

Fresh fruits of Carica papaya L. were purchased from local market and used for this study. The skin was peeled off, seeds were removed and the pulp was cut into pieces. 500g of the fruits was weighed and filtered using a Whatman filter paper 125 mm and concentrated using a rotary evaporator.

Cafeteria Diets (High Fat Diet)

The cafeteria diet consisted of 3 diets (condensed milk, 40g + bread, 40g), (chocolate, 15g + biscuits, 30g + dried coconut, 30g), (cheese, 40g + boiled potatoes, 50g). The three diets were presented to group of 6 rats on day 1, 2 and 3 respectively and then repeated in same succession. These diets were provided in addition to normal pellet chow.

Experimental Design

The rats were divided into six groups with six rats each:

- **Group I**: Normal Diet (ND) Fed or Normal Control
- **Group II**: High Fat Cafeteria Diet (HFD) Fed or Obesity control
- **Group III**: HFD + Aqueous fruit extract of Carica papaya L. (200mg/kg b.w.)
- **Group IV**: HFD + Aqueous fruit extract of Carica papaya L. (400mg/kg b.w.)
- **Group V**: HFD + Aqueous fruit extract of Carica papaya L. (600mg/kg b.w.)
- **Group VI**: HFD + Standard Drug, Orlistat (50mg/kg b.w.)
All the drugs were given orally for a period of 45 days. At the end of experimental period the animals were sacrificed by cervical decapitation. The blood was collected and the serum was separated and used for various biochemical analyses. The liver, kidney and spleen were dissected out, washed in ice cold saline and weighed. Liver tissues were homogenized in 0.1M phosphate buffer (pH 7.4) and used for the analysis of hepatic lipids and antioxidants.

**Biochemical Analysis**

Blood glucose content was estimated by Folin- Wu method. Tissue lipids were extracted by the method of Fokh et al.\(^\text{11}\). Total cholesterol, Triglycerides, Phospholipids, Free fatty acids and Serum HDL-Cholesterol\(^\text{11}\) were determined using their standard procedures. The LDL\(^\text{11}\) and VLDL-Cholesterol were determined using the following formulas:

- LDL-Cholesterol = Total Cholesterol – (HDL-C – {Triglyceride/5})
- VLDL-Cholesterol = Total Serum Triglyceride/5

Lipid peroxide content was measured by the method of Ohkawa\(^\text{12}\). Reduced Glutathione was estimated using the method of Sedlak et al.\(^\text{13}\). The assay of SOD was carried out using the method of Misra and Fridovich\(^\text{14}\).

In addition to these, physical parameters such as daily food intake and body weight (weekly) were also determined.

**Statistical Analysis**

All the data reported are expressed as mean ± S.E.M. Statistical analysis was performed by one-way analysis of variance (ANOVA). The values were considered to be significantly different when the P-value was less than 0.05 compared to baseline or control values.

**RESULTS AND DISCUSSION**

**Effect on Body Weight**

After 45 days of feeding, body weights in the high fat cafeteria diet (HFD) group were heavier than those of the normal diet (ND) group. Moreover, the body weights of the HFD+AFECP (Aqueous Fruit Extract of Carica papaya L) treated groups were significantly decreased in a dose dependent manner as compared to the HFD group (Figure 1).

**Effect on Organ Weight**

The absolute weights of liver, kidney and spleen of HFD group were significantly higher when compared to ND group animals. This could be related to an accumulation of TG and cholesterol in these organs. There were no abnormalities in growth performance; however, the relative weights of the liver, kidney and spleen were significantly lower in the AFECP treated groups as compared to the HFD group. This is probably because of the lower fat content in those tissues (Table 1).

**Effect on Body Mass Index (BMI)**

There was a significant increase in the BMI of HFD group animals as compared to the ND group. The increased BMI demonstrated the efficiency of cafeteria diet to induce obesity in these animals. Moreover, the treatment with AFECP maintained the BMI compared to that of ND group (Table 1).

**Table 1: Effect of AFECP on Organ Weight and BMI in HFD Induced Obese Rats**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Liver (g)</th>
<th>Kidney (g)</th>
<th>Spleen (g)</th>
<th>BMI (g/cm(^2))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>6.678 ± 1.48(^*)</td>
<td>1.249 ± 0.61(^*)</td>
<td>0.587 ± 0.40(^*)</td>
<td>0.691 ± 0.28(^*)</td>
</tr>
<tr>
<td>Group II</td>
<td>9.529 ± 1.30(^**)</td>
<td>1.652 ± 0.05(^**)</td>
<td>0.852 ± 0.15(^**)</td>
<td>0.733 ± 1.43(^**)</td>
</tr>
<tr>
<td>Group III</td>
<td>7.849 ± 1.15</td>
<td>1.561 ± 0.91</td>
<td>0.683 ± 1.01</td>
<td>0.698 ± 1.98</td>
</tr>
<tr>
<td>Group IV</td>
<td>7.338 ± 0.94</td>
<td>1.501 ± 1.01</td>
<td>0.613 ± 0.98</td>
<td>0.693 ± 1.08</td>
</tr>
<tr>
<td>Group V</td>
<td>6.772 ± 0.50(^**)</td>
<td>1.4 ± 0.79(^**)</td>
<td>0.598 ± 0.17(^**)</td>
<td>0.692 ± 0.14(^**)</td>
</tr>
<tr>
<td>Group VI</td>
<td>6.52 ± 1.55</td>
<td>1.125 ± 0.07</td>
<td>0.565 ± 0.07</td>
<td>0.662 ± 1.09</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M., (n = 6)

\(^*\) - Compared between Normal and Disease Control (p<0.05).

\(^**\) - Compared between Disease Control and High Dose Drug Treated Group (p<0.05).
Effect on Blood Glucose

There was a significant increase in serum glucose level in HFD group when compared to ND group. The significant increase in glucose in high fat cafeteria diet fed animal can be attributed to defective insulin signaling and a decreased insulin efficiency to induce glucose transport from the blood into key target cells such as muscle and fat (adipocyte) cells. Treatment with AFECP almost normalized the glucose levels in dose dependent manner. This could be probably mediated through enhanced secretion of insulin from the β-cells of the islets of pancreas or through an extra pancreatic mechanism.

Effect on Serum Lipid Profile

The levels of serum lipid profile such as total cholesterol (TC), Triglycerides (TG) and lipoproteins such as Low Density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C) were significantly elevated in the HFD group, while High Density Lipoprotein Cholesterol (HDL-C) was significantly decreased as compared to the ND group. However, administration of AFECP significantly improved these changes in a dose dependent manner (Table 2).

The significant increase in total cholesterol and triglyceride level in HFD animals can be attributed to increase in both hypercholestremia, which is one of the risk factors for CAD.

A substantial reduction of total cholesterol in serum by AFECP could be attributed to a reduction in the activities of the liver enzyme 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, which is a rate-limiting enzyme in cholesterol biosynthesis. Also, a substantial reduction in LDL-cholesterol and total cholesterol level in serum could be achieved by decreased production of total cholesterol by liver tissue and/or efficient removal of the LDL-cholesterol by various tissues without subsequent renewal. A higher content of HDL-C is very important because it is correlated with a reduced risk of coronary heart disease. The increased HDL facilitates the transport of cholesterol from the serum to the liver, where it is catabolized and excreted from the body. The decrease of TG in AFECP treated group may be related to increase in endothelium bound lipoprotein lipase activity that hydrolyses the triglycerides into fatty acids.

Effect on Hepatic Lipid

The levels of hepatic lipid profile such as total cholesterol (TC), Triglycerides (TG) Phospholipids (PL) and Free Fatty Acid (FFA) were significantly elevated in the HFD group, however, administration of AFECP significantly restored these changes in a dose dependent manner (Table 3). This indicated AFECP efficiently regulated triglyceride and cholesterol metabolism. This may be accomplished through the decreased expression of genes for fatty acid synthesis and enhanced activation of expression of genes for β-oxidation.

Table 2: Effect of AFECP on Blood Glucose and Serum Lipid Profiles in HFD Induced Obese Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>Glucose (mg/dl)</th>
<th>Serum Lipid Profiles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Total Cholesterol (mg/dl)</td>
</tr>
<tr>
<td>Group I</td>
<td>74.16 ± 0.62*</td>
<td>110.76 ± 0.75*</td>
</tr>
<tr>
<td>Group II</td>
<td>148.3 ± 1.66***</td>
<td>182.14 ± 1.23***</td>
</tr>
<tr>
<td>Group III</td>
<td>120.96 ± 1.63</td>
<td>169.38 ± 0.87</td>
</tr>
<tr>
<td>Group IV</td>
<td>98.06 ± 1.80</td>
<td>130.8 ± 1.62</td>
</tr>
<tr>
<td>Group V</td>
<td>80.7 ± 0.16</td>
<td>109.48 ± 1.47</td>
</tr>
<tr>
<td>Group VI</td>
<td>71.64 ± 1.70</td>
<td>107.8 ± 0.75</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M., (n = 6)
* - Compared between Normal and Disease Control (p<0.05).
** - Compared between Disease Control and High Dose Drug Treated Group (p<0.05).

Table 3: Effect of AFECP on Hepatic Lipid Profiles in HFD Induced Obese Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>Total Cholesterol (mg/g tissue)</th>
<th>Triglycerides (mg/g tissue)</th>
<th>Phospholipids (mg/g tissue)</th>
<th>Free Fatty Acid (µEq/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>4.62 ± 0.93</td>
<td>34 ± 0.95</td>
<td>26.74 ± 1.06</td>
<td>5.38 ± 1.09</td>
</tr>
<tr>
<td>Group II</td>
<td>9.4 ± 0.84***</td>
<td>78 ± 0.88***</td>
<td>35.54 ± 1.82***</td>
<td>11.47 ± 0.95***</td>
</tr>
<tr>
<td>Group III</td>
<td>88.2 ± 1.57</td>
<td>72.34 ± 2.07</td>
<td>32.85 ± 2.15</td>
<td>11.21 ± 1.28</td>
</tr>
<tr>
<td>Group IV</td>
<td>6.93 ± 1.09</td>
<td>58.5 ± 1.52</td>
<td>30.72 ± 2.06</td>
<td>9.83 ± 2.07</td>
</tr>
<tr>
<td>Group V</td>
<td>5.38 ± 0.85**</td>
<td>49.12 ± 1.08*</td>
<td>28.07 ± 1.02*</td>
<td>7.06 ± 0.99*</td>
</tr>
<tr>
<td>Group VI</td>
<td>4.99 ± 0.09</td>
<td>37.18 ± 0.93</td>
<td>26.49 ± 0.95</td>
<td>5.8 ± 0.56</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M., (n = 6)
* - Compared between Normal and Disease Control (p<0.05).
** - Compared between Disease Control and High Dose Drug Treated Group (p<0.05).

Table 4: Effect of AFECP on Hepatic Antioxidants in HFD Induced Obese Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>LPO (n moles of MDA formed/g tissue)</th>
<th>GSH (mg/g tissue)</th>
<th>SOD Activity (Unit/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>97.33 ± 1.99*</td>
<td>4.40 ± 1.07</td>
<td>3.93 ± 1.85</td>
</tr>
<tr>
<td>Group II</td>
<td>142.2 ± 0.95***</td>
<td>2.17 ± 0.64**</td>
<td>1.05 ± 0.44**</td>
</tr>
<tr>
<td>Group III</td>
<td>138.84 ± 1.19</td>
<td>3.12 ± 1.29</td>
<td>2.25 ± 1.32</td>
</tr>
<tr>
<td>Group IV</td>
<td>132.28 ± 1.07</td>
<td>3.63 ± 0.57</td>
<td>2.88 ± 0.71</td>
</tr>
<tr>
<td>Group V</td>
<td>126.81 ± 0.63*</td>
<td>4.18 ± 0.62**</td>
<td>3.41 ± 0.69**</td>
</tr>
<tr>
<td>Group VI</td>
<td>111.18 ± 0.56</td>
<td>4.28 ± 0.38</td>
<td>3.89 ± 0.06</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M., (n = 6)
* - Compared between Normal and Disease Control (p<0.05).
** - Compared between Disease Control and High Dose Drug Treated Group (p<0.05).
Effect on Antioxidants

HFD generates oxidative stress in obese rats as shown by a marked increase in the levels of MDA and a distinct diminution in hepatic GSH, as well as activities of the antioxidant enzyme SOD. All showed reduced activity in obese or hyperlipidemic rats (Table: 4).

Generally obesity is associated with a decrease in tissue or plasma antioxidant capacity. Several studies have shown increased lipid peroxidation in clinical and experimental hyperlipidemia. It has been established that hyperlipidemia leads to increased production of oxygen free radicals which exert their cytotoxic effect by causing lipid peroxidation.

GSH constitutes the first line of defense against free radicals in the liver, and it is also responsible for the maintenance of protein thiols and acting as a substrate for Gpx. Hyperglycemia in the HFD group activates different pathways leading to increased oxidative stress. Increased activity of the polyol pathway, inhibition of the pentose phosphate pathway as a result of hyperglycemia resulted in decreased intracellular levels of NADPH, which is required for regeneration of GSH from its oxidized form GSSG. The net result was non-enzymatic disruption of H2O2 and increased levels of cellular superoxides, hydroperoxides, hydroxyl radicals as well as other radicals.

SODs are a family of antioxidant enzyme which are important in the catalytic decomposition of the superoxide radical which are formed during aerobic metabolism. Feeding a HFD to animals depresses the SOD activity due to increased lipid peroxidation and formation of excessive free radicals.

In addition, oxidative stress may be increased in metabolic syndrome due to dyslipidemia resulting from increased levels of FFA and TGs that led to increased formation of foam cells, rendering LDL more dense and more vulnerable to oxidation and uptake by macrophages.

On treatment with AFECP produced a significant inhibition of MDA production and a significant increase in GSH and activity of SOD. The test drug might have been inhibiting the lipase activity which resulted in decreased lipid content in hepatic tissue which in turn decreased the lipid peroxidation. This potent antioxidant effect of aqueous fruit extract of C. papaya L. might be contributed by its rich antioxidant contents such as vitamin C, β-carotene and other flavonoid compounds.

CONCLUSION

In conclusion, these data indicates that aqueous fruit extract of C. papaya L. appears to be a promising health drink capable of modulating weight control without inducing any adverse side effects. Further studies can be undertaken to establish the possible mechanism of action of C. papaya L. fruit extract. This could include measuring serum leptin levels, serum insulin levels, serum lipoprotein lipase activity, pancreatic lipase activity, brown adipose tissue mass and other neurotransmitters involved in control of appetite.

REFERENCES


